Navigation Links
WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
Date:5/26/2008

SHANGHAI, China, May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has appointed Dr. Peng Wang as Vice President of Discovery Biology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi PharmaTech, Dr. Wang was a research fellow at Schering-Plough Research Institute where he worked for 18 years with increasing responsibilities. He has extensive experience in discovery biology, including target validation research, assay development, screening, in vitro and in vivo biological and pharmacological studies, and mechanism of action and biomarker research. As a discovery team co-chair and biology group leader at Schering-Plough, Dr. Wang made significant contributions to the nomination of several development candidates, four of which are at various phases of clinical trial.

In his new role as Vice President of Discovery Biology, Dr. Wang will oversee the company's growing portfolio of discovery biology service offerings. Dr. Wang will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

"I am very delighted to welcome Dr. Wang on board at this exciting time. Dr. Wang's depth of experience will undoubtedly help the company to accelerate the development of our discovery biology services, and strengthen our medicinal chemistry and biologics discovery capabilities," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, Japan, and has published numerous original biological research articles in the leading and peer-reviewed scientific journals.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
2. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
3. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
4. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
5. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
6. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
7. WuXi PharmaTech Completes Acquisition of AppTec
8. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
11. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/24/2016)... May 24, 2016   MedyMatch Technology Ltd ., the ... intelligence, real-time decision support tools in the emergency room, announced ... 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... 15th National Life Sciences and Technology Week, and ... Intercontinental Hotel in Tel Aviv, Israel . ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
Breaking Biology Technology:
(Date:3/9/2016)... PALM BEACH GARDENS, Fla. , March 9, ... of identity management authentication and enrollment solutions, today ... proven DigitalPersona ® Altus multi-factor ... enable IT and InfoSec managers to step-up security ... friction.  Washington, DC ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, ... Plus® to offer Oncimmune,s Early CDT®-Lung, a blood ... detection of lung cancer Early CDT®-Lung test ... individuals. --> Early CDT®-Lung test to its ... --> Oncimmune, a leader in early cancer detection, ...
Breaking Biology News(10 mins):